文章：

3D打印支架中树突状细胞疫苗的原位生成用于癌症术后治疗

In Situ generation of dendritic cell vaccines in 3D printing scaffolds for cancer post-surgical therapy

原文发布日期：2026-01-20

DOI: 10.1093/nsr/nwag037

类型: Journal Article

开放获取: 是

英文摘要：

Dendritic cell (DC) vaccines have shown great promise in cancer management, while complex ex vivo cell culture limits their clinical applications. Here, we report an in situ generated scaffold DC vaccine, comprising a simple 3D printing of gelatin methacryloyl, bone marrow mononuclear cells (BM-MNCs), tumor lysates, and stimulating factors. Stimulating factors in this vaccine effectively initiated in situ differentiation of BM-MNCs into DCs, while personalized tumor lysates stimulated the maturation of differentiated DCs and enhanced their lymph nodes migration efficiency, thereby synergistically strengthening their antitumor effects. Moreover, 3D hydrogel scaffold serves as an in situ cell culture matrix, promoting the long-term viability of encapsulated cells and providing a conducive environment for BM-MNCs differentiation and DC maturation within the surgical bed. In prostate cancer post-surgical mouse models, the vaccine significantly inhibited tumor growth, suppressed tumor metastasis, and extended median survival of animals to 55 days. This in situ generated DC vaccine bypasses ex vivo cell culture, offering a simple, safe and robust strategy to elicit antitumor immunity for cancer treatment.

摘要翻译： 

树突状细胞（DC）疫苗在癌症治疗中展现出巨大潜力，但其复杂的体外细胞培养过程限制了临床应用。本文报道了一种原位生成支架型DC疫苗，该疫苗通过简单3D打印整合明胶甲基丙烯酰、骨髓单核细胞（BM-MNCs）、肿瘤裂解液及刺激因子构成。疫苗中的刺激因子有效启动了BM-MNCs向DCs的原位分化，而个体化肿瘤裂解液则促进分化后DCs的成熟并提升其淋巴结迁移效率，从而协同增强抗肿瘤效应。此外，3D水凝胶支架作为原位细胞培养基质，既能维持封装细胞的长期存活能力，又为手术床区域内BM-MNCs的分化及DCs成熟提供了有利环境。在前列腺癌术后小鼠模型中，该疫苗显著抑制了肿瘤生长与转移，并将动物中位生存期延长至55天。这种原位生成DC疫苗避免了体外细胞培养环节，为癌症免疫治疗提供了一种简便、安全且高效的策略。

原文链接：

In Situ generation of dendritic cell vaccines in 3D printing scaffolds for cancer post-surgical therapy